TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18477087

Group type: EXPERIMENTAL
Intervention: ANH with oxygen insufflation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ANH with air insufflation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 15981753

Group type: EXPERIMENTAL
Intervention: Dinamap
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Criticare
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hewlett-Packard
Number of subjects: 20

Group type: COMPARATOR
Intervention: Invasive blood pressure measurement (Hewlett-Packard invasive unit)
Number of subjects: 20
Study: 12710787

Group type: EXPERIMENTAL
Intervention: Flex-Guide (FG) Endotracheal Tube (ETT) introducer
Number of subjects: 96

Group type: COMPARATOR
Intervention: Stylet ETT intubation
Number of subjects: 96
Study: 10340796

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (mecobalamin)
Number of subjects: 66
Study: 8636344

Group type: EXPERIMENTAL
Intervention: GH administration (0.1 IU/kg x day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: T3 administration (40 microg on even dates, 20 microg on uneven dates)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined GH and T3 administration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo injections and placebo tablets
Number of subjects: 8
Study: 1767711

Group type: EXPERIMENTAL
Intervention: H2 blockers (Ranitidine 300 mg or Famotidine 40 mg)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Double dose of H2 receptor antagonists or sucralfate (4 gr/day)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg, single dose
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Maintenance therapy (ranitidine 150 mg or famotidine 20 mg)
Number of subjects: 154

Group type: COMPARATOR
Intervention: No maintenance therapy
Number of subjects: 154
Study: 6127150

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg intravenously
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Ranitidine 100 mg intravenously
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg intravenously
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg orally
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg orally
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 30875890

Group type: EXPERIMENTAL
Intervention: Stand-biased desk
Number of subjects: 99

Group type: COMPARATOR
Intervention: Traditional desk
Number of subjects: 99
Study: 28476273

Group type: EXPERIMENTAL
Intervention: A‐CHESS intervention (smartphone application and 8‐month service plan)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control (treatment as usual)
Number of subjects: 349
Study: 26241419

Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study: 23611172

Group type: EXPERIMENTAL
Intervention: Bisoprolol 2.5mg/day for 2 weeks
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5mg/day for 2 weeks
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Bisoprolol 2.5mg/day continuation for 2 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Comparison between 5mg and 2.5mg continuation groups
Number of subjects: 78

Group type: COMPARATOR
Intervention: 5mg group vs 2.5mg continuation group
Number of subjects: 78
Study: 21369370

Group type: EXPERIMENTAL
Intervention: Valsalva maneuver (Group III); blew into sphygmomanometer tubing and hold the mercury column up to 30 mm Hg for at least 20s
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (Group I)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ball (Group II); pressed a rubber ball (attention‐diverting method)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 19470677

Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 227

Group type: COMPARATOR
Intervention: Daclizumab
Number of subjects: 227
Study: 17083009

Group type: EXPERIMENTAL
Intervention: MenCV (serogroup C meningococcal glycoconjugate vaccine)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: MenCV
Number of subjects: 274

Group type: COMPARATOR
Intervention: MenPS (meningococcal AC plain polysaccharide vaccine)
Number of subjects: 274
Study: 14733856

Group type: EXPERIMENTAL
Intervention: Rifampicine (R) + Pirazinamide (Z) for 2 months
Number of subjects: 172

Group type: COMPARATOR
Intervention: Isoniazid (H) for 6 months
Number of subjects: 172
Study: 11317704

Group type: COMPARATOR
Intervention: Normal pressure (100 kPa)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Raised ambient pressure (400 kPa)
Number of subjects: 23
Study: 9125680

Group type: EXPERIMENTAL
Intervention: Acetylcholine (0.15, 0.45, 1.5, 4.5, and 15 microg/100 ml forearm tissue/min)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sodium nitroprusside (1, 2, and 4 microg/100 ml forearm tissue/min)
Number of subjects: 17
Study: 7648143

Group type: EXPERIMENTAL
Intervention: Daflon 500 mg for 1 week after operation (group 1)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 228
Study: 2744313

Group type: EXPERIMENTAL
Intervention: Gallopamil 25 mg tid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gallopamil 50 mg tid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 820813

Group type: EXPERIMENTAL
Intervention: Severe malnutrition
Number of subjects: 97

Group type: COMPARATOR
Intervention: Antibiotic usage
Number of subjects: 97

Group type: COMPARATOR
Intervention: Presence of intestinal parasites
Number of subjects: 97

Group type: COMPARATOR
Intervention: Refeeding diet
Number of subjects: 97
Study: 31374140

Group type: EXPERIMENTAL
Intervention: LMIC authors
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: HIC authors
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Respondents
Number of subjects: 279
Study: 25278342

Group type: EXPERIMENTAL
Intervention: Self-control strength training (maximal endurance contractions of spring handgrip trainers, twice daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No-treatment control group (trial-matched cognitive task)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No-treatment control group (time-matched cognitive task)
Number of subjects: 41
Study: 23298651

Group type: EXPERIMENTAL
Intervention: Varenicline (1mg twice per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20851591

Group type: EXPERIMENTAL
Intervention: Helium-oxygen
Number of subjects: 10
Study: 18838742

Group type: EXPERIMENTAL
Intervention: Persisting high burden group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Caregivers without persisting high burden
Number of subjects: 33
Study: 17072792

Group type: EXPERIMENTAL
Intervention: Bilateral STN stimulation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Unilateral pallidotomy
Number of subjects: 34
Study: 12971556

Group type: EXPERIMENTAL
Intervention: DNP (dihydroartemisinin-napthoquine-trimethoprim), one tablet twice a day for one day
Number of subjects: 130

Group type: COMPARATOR
Intervention: Coartem/Riamet (artemether-lumefantrine), four tablets twice a day for 3 days
Number of subjects: 130
Study: 10864055

Group type: EXPERIMENTAL
Intervention: ABCD (amphotericin B colloidal dispersion)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ABCD (in open-label studies)
Number of subjects: 49
Study: 8971295

Group type: EXPERIMENTAL
Intervention: Colchicine 5 mg/week
Number of subjects: 65

Group type: COMPARATOR
Intervention: No specific treatment (Control)
Number of subjects: 65
Study: 1297643

Group type: EXPERIMENTAL
Intervention: 600 mg granular ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6395810

Group type: EXPERIMENTAL
Intervention: Twice daily sustained release theophylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31783739

Group type: EXPERIMENTAL
Intervention: EPA-rich fish oil supplement
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil supplement
Number of subjects: 126

Group type: COMPARATOR
Intervention: Soy oil placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Maternal serum DHA fraction
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Cord blood DHA fraction
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Early pregnancy BMI
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Pregnancy weight gain
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: ALR
Number of subjects: 126
Study: 28372514

Group type: EXPERIMENTAL
Intervention: Surveyed group (received pre-screening lifestyle questionnaire)
Number of subjects: 10375

Group type: COMPARATOR
Intervention: Not surveyed group (no pre-screening lifestyle questionnaire)
Number of subjects: 10375
Study: 25185016

Group type: EXPERIMENTAL
Intervention: Single-cuff self-locating catheters (SLCs)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Single-cuff straight Tenckhoff catheter (TC)
Number of subjects: 78
Study: 24590325

Group type: EXPERIMENTAL
Intervention: Distally based perforator-plus sural fasciocutaneous flap in pediatric group
Number of subjects: 201

Group type: COMPARATOR
Intervention: Distally based perforator-plus sural fasciocutaneous flap in adult group
Number of subjects: 201
Study: 22273718

Group type: EXPERIMENTAL
Intervention: Wilms tumor 1 peptide vaccine plus gemcitabine and cisplatin (GC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gemcitabine and cisplatin (GC)
Number of subjects: 100
Study: 19395583

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) infusion (50 mg/kg body mass)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 13
Study: 17466725

Group type: EXPERIMENTAL
Intervention: Back Rx program (15 minutes a day, 3 times a week)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Medications and cryobrace alone (Control group)
Number of subjects: 50
Study: 15951880

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Home-based exercise training
Number of subjects: 22
Study: 12704885

Group type: EXPERIMENTAL
Intervention: Jejunum pouch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple Roux-en-Y limb
Number of subjects: 0
Study: 9433873

Group type: EXPERIMENTAL
Intervention: Avocado/Soybean Unsaponifiables (ASU)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 7661424

Group type: EXPERIMENTAL
Intervention: Trinder spot test performed by emergency physicians
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Serum quantitative assays
Number of subjects: 12
Study: 2388876

Group type: EXPERIMENTAL
Intervention: Home therapeutic drug-monitoring (TDM) method for theophylline blood levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional TDM method (controls)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home TDM
Number of subjects: 0
Study: 26520

Group type: EXPERIMENTAL
Intervention: Nadolol (100 mg once daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Propranolol (112 mg 4-times daily)
Number of subjects: 24
Study: 31566937

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (25 mg/m² IV every 3 weeks, plus prednisone daily and granulocyte colony-stimulating factor)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Androgen-signaling-targeted inhibitor (1000 mg of abiraterone plus prednisone daily or 160 mg of enzalutamide daily)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 255

Group type: COMPARATOR
Intervention: Androgen-signaling-targeted inhibitor
Number of subjects: 255
Study: 27847247

Group type: EXPERIMENTAL
Intervention: Sodium alginate initiated concomitantly with CRT (group A)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sodium alginate initiated soon after the development of extremely mild esophagitis during CRT (group B)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Water administered throughout CRT (group C)
Number of subjects: 200
Study: 25881694

Group type: EXPERIMENTAL
Intervention: Core stabilization exercises
Number of subjects: 28
Study: 23965236

Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM) with remote follow‐up and wireless automatic alerts
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group with standard follow‐up without alerts
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM) and Control group
Number of subjects: 154
Study: 22299554

Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (routine treatment with atropine and pralidoxime)
Number of subjects: 56
Study: 19216850

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) therapy for clearing heat and resolving phlegm combined with routine Western medicine.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine Western medicine only (control group).
Number of subjects: 100
Study: 17110256

Group type: EXPERIMENTAL
Intervention: Twin-block appliance
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Bionator appliance
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 15577269

Group type: EXPERIMENTAL
Intervention: Pharmacists provided regular instructions on Nicorette use and smoking cessation advice at the first sale and follow-up advice at 1, 3, 8 weeks and 3 months thereafter (Intervention group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Regular instructions alone (Control group B)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pharmacists provided regular instructions on Nicorette use and smoking cessation advice (Intervention group A)
Number of subjects: 28
Study: 11740214

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 9006561

Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery (BCS) in British Columbia
Number of subjects: 1880

Group type: COMPARATOR
Intervention: Breast-conserving surgery (BCS) in Ontario
Number of subjects: 1880

Group type: EXPERIMENTAL
Intervention: Radiation therapy after BCS in British Columbia
Number of subjects: 1880

Group type: COMPARATOR
Intervention: Radiation therapy after BCS in Ontario
Number of subjects: 1880
Study: 8255111

Group type: EXPERIMENTAL
Intervention: Neuro-reflexotherapic intervention
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (inappropriate zones stimulated)
Number of subjects: 91
Study: 3105748

Group type: EXPERIMENTAL
Intervention: Thyroxine (150 micrograms daily)
Number of subjects: 110

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 110
Study: 29785103

Group type: EXPERIMENTAL
Intervention: Chinese version of the Severe Respiratory Insufficiency Questionnaire (SRI)
Number of subjects: 161
Study: 27607036

Group type: EXPERIMENTAL
Intervention: 2% Potentilla officinalis (PO) cream
Number of subjects: 64

Group type: COMPARATOR
Intervention: 1% hydrocortisone acetate cream
Number of subjects: 64
Study: 24652604

Group type: EXPERIMENTAL
Intervention: TJ-14
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 22336189

Group type: EXPERIMENTAL
Intervention: Cardiosphere-derived cells (CDCs) infused into the infarct-related artery 1.5-3 months after myocardial infarction.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cardiosphere-derived cells (CDCs) compared to standard care at 6 months.
Number of subjects: 31
Study: 20517672

Group type: EXPERIMENTAL
Intervention: Pregabalin (150-300 mg daily for three weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 29
Study: 18721243

Group type: EXPERIMENTAL
Intervention: Dexamethasone 21‐P (Dex 21‐P) encapsulated into erythrocytes (DEE), 9.9 +/- 4.1 mg per infusion, two infusions 14 days apart (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (0.5 mg/kg for 14 days followed by a 6 mg/weekly tapering, group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham infusions (group C)
Number of subjects: 40
Study: 16358106

Group type: EXPERIMENTAL
Intervention: Aerobic fitness program (ergometer cycle sessions 3 times a week for six months at VT‐1 intensity)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no changes in activities or exercise program)
Number of subjects: 46
Study: 12472985

Group type: EXPERIMENTAL
Intervention: Haloperidol 20 mg/day plus Diazoxide 200 mg/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Haloperidol 20 mg/day plus Placebo
Number of subjects: 42
Study: 10343133

Group type: EXPERIMENTAL
Intervention: La1 supernatant with omeprazole 20 mg four times a day
Number of subjects: 20

Group type: COMPARATOR
Intervention: La1 supernatant with placebo
Number of subjects: 20
Study: 8881868

Group type: EXPERIMENTAL
Intervention: dopexamine hydrochloride
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study: 2028084

Group type: EXPERIMENTAL
Intervention: Blocked trials
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Random trials
Number of subjects: 16
Study: 7438683

Group type: EXPERIMENTAL
Intervention: Ethanol 0.7 gm/kg orally over 15 min followed by diazepam 10 mg intravenously over 20 min and ethanol 0.15 gm/kg/hr for 8 hr
Number of subjects: 6

Group type: COMPARATOR
Intervention: Diazepam 10 mg intravenously over 20 min
Number of subjects: 6
Study: 31132798

Group type: EXPERIMENTAL
Intervention: Serum visfatin levels during follow-up (2013)
Number of subjects: 2429

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) during follow-up (2013)
Number of subjects: 2429

Group type: EXPERIMENTAL
Intervention: Waist-to-hip ratio during follow-up (2013)
Number of subjects: 2429

Group type: EXPERIMENTAL
Intervention: Triglycerides (TG) during follow-up (2013)
Number of subjects: 2429

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein (LDL) during follow-up (2013)
Number of subjects: 2429

Group type: EXPERIMENTAL
Intervention: Homeostasis model assessment during follow-up (2013)
Number of subjects: 2429

Group type: EXPERIMENTAL
Intervention: Presence of diabetes during follow-up (2013)
Number of subjects: 2429

Group type: EXPERIMENTAL
Intervention: Correlation of serum visfatin with BMI
Number of subjects: 2429

Group type: EXPERIMENTAL
Intervention: Correlation of serum visfatin with presence of diabetes
Number of subjects: 2429

Group type: EXPERIMENTAL
Intervention: Correlation of leucocyte numbers with serum visfatin concentration
Number of subjects: 2429
Study: 28034908

Group type: EXPERIMENTAL
Intervention: Room Air (RA)
Number of subjects: 287

Group type: COMPARATOR
Intervention: 100% O2
Number of subjects: 287
Study: 25774062

Group type: EXPERIMENTAL
Intervention: Total contact insoles (TCI) made of ethylene vinyl acetate
Number of subjects: 74

Group type: COMPARATOR
Intervention: Flat insole (control group)
Number of subjects: 74
Study: 23817868

Group type: EXPERIMENTAL
Intervention: Portable vocal amplifier for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Course only (no amplifier)
Number of subjects: 40
Study: 21069377

Group type: EXPERIMENTAL
Intervention: Mixed antioxidant supplementation (vitamin C & E)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 19767093

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2, day 1) plus best supportive care (n=441)
Number of subjects: 663

Group type: COMPARATOR
Intervention: Placebo plus best supportive care (n=222)
Number of subjects: 663
Study: 17445781

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 15370494

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 11331168

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine with fentanyl (2 micro g.ml(‐1))
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine with sufentanil (0.25 micro g.ml(‐1))
Number of subjects: 226
Study: 9288222

Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 8198902

Group type: EXPERIMENTAL
Intervention: Intra-tracheal adrenaline (up to 10 micrograms kg‐1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous adrenaline (0.1 microgram kg‐1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intra-tracheal doses recommended for resuscitation (2-3 mg)
Number of subjects: 16
Study: 3131068

Group type: EXPERIMENTAL
Intervention: Pulse oximetry and capnometry monitoring
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Capnometry monitoring
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group monitored with periodic ABG sampling
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Experimental group monitored by following PetCO2 and O2 Sat via pulse oximetry
Number of subjects: 40
Study: 29411359

Group type: EXPERIMENTAL
Intervention: Bougie-guided intubation
Number of subjects: 124

Group type: COMPARATOR
Intervention: Wire-guided intubation
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 124
Study: 27163253

Group type: EXPERIMENTAL
Intervention: Enriched air nitrox (EAN) breathing (36% O2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Compressed air breathing
Number of subjects: 12
Study: 25637322

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 39173

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 39173

Group type: COMPARATOR
Intervention: Atorvastatin (various doses)
Number of subjects: 39173

Group type: EXPERIMENTAL
Intervention: LDL cholesterol levels
Number of subjects: 39173
Study: 22453059

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol) 50,000 IU, 3 oral capsules every 20 days for two months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 20693884

Group type: EXPERIMENTAL
Intervention: Fentanyl-acetaminophen group
Number of subjects: 63